Recombinant Human TGF-beta 2
Recombinant Human Transforming Growth Factor Beta 2 is produced by our Mammalian expression system and the target gene encoding Ala303-Ser414 is expressed.
Description
| Reference | ESCIT195 |
|---|---|
| Size | 10ug |
| Molecular Weight | 12.7 KDa |
| Purity | Greater than 95% as determined by reducing SDS-PAGE. |
| Endotoxin | Less than 0.001 ng/µg (0.01 EU/µg) as determined by LAL test. |
| Biological Activity | Immobilized Human TGF-beta 2(Cat#CJ79) at 2?g/ml (100 ?l/well)can bind Human TGFBR2-Fc (Cat#CC10).The ED50 of Human TGFBR2-Fc (Cat#CC10) is 1.15 ug/ml. |
Other names: Transforming growth factor beta-2; TGFB2; Polyergin; G-TSF; Glioblastoma-derived T-cell suppressor factor; Cetermin; BSC-1 cell growth inhibitor; TGF-beta-2
Redissolve: Always centrifuge tubes before opening.Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100?g/ml.
Dissolve the lyophilized protein in distilled water.
Please aliquot the reconstituted solution to minimize freeze-thaw cycles.
Storage: Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Background: Transforming growth factor beta-2 (TGF-?2) is a secreted protein which belongs to the TGF-beta family. It is known as a cytokine that performs many cellular functions and has a vital role during embryonic development. The precursor is cleaved into mature TGF-beta-2 and LAP, which remains non-covalently linked to mature TGF-beta-2 rendering it inactive. It is an extracellular glycosylated protein. It is known to suppress the effects of interleukin dESCIendent T-cell tumors. Defects in TGFB2 may be a cause of non-syndromic aortic disease (NSAD).